title: [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
abstract: Familial amyloid polyneuropathy (FAP) is an autosomal dominant genetic disorder with systemic deposition of amyloid fibrils, and is characterized by progressive sensory, motor, and autonomic polyneuropathy. FAP was considered a rare endemic disease; however, its worldwide incidence is much higher than previously recognized. Until recently, liver transplantation was the only effective treatment for FAP. However, liver transplantation has a number of limitations, including a shortage of donors and a requirement for surgery for both the recipient and living donor. Furthermore, a large number of the patients are not good transplant candidates because of their age and/or advanced disease status. Recently, the clinical effects of two transthyretin tetramer stabilizers, diflunisal and tafamidis, were demonstrated in randomized clinical trials, and tafamidis was approved for the treatment of FAP in European countries in 2011 and Japan in 2013.
authors.affiliation: Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sekijima
mesh_terms: D028227:Amyloid Neuropathies, Familial / Q000188:drug therapy* / Q000378:metabolism; D001583:Benzoxazoles / Q000627:therapeutic use*; D004061:Diflunisal / Q000627:therapeutic use*; D006801:Humans; D016031:Liver Transplantation; D058990:Molecular Targeted Therapy; D011228:Prealbumin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D055503:Protein Multimerization
chemical_list: D001583:Benzoxazoles; D011228:Prealbumin; D004061:Diflunisal; C547076:tafamidis